NasdaqCM:BLTEPharmaceuticals
Belite Bio (BLTE) Valuation Check After Completing Enrollment In Pivotal DRAGON II Trial
Belite Bio (BLTE) completed enrollment of 60 adolescents in its global Phase 2/3 DRAGON II trial for tinlarebant in Stargardt disease type 1, marking a key clinical milestone that investors often watch closely.
See our latest analysis for Belite Bio.
The latest clinical milestone comes on top of a strong run in the shares, with Belite Bio’s 30 day share price return of 18.63% and 90 day share price return of 77.63%. Its 1 year total shareholder return of 249.18% and 3 year total shareholder...